University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora CO 80045, USA.
Oncology (Williston Park). 2012 Jan;26(1):70-7.
The rapid approval of several novel agents has given prostate cancer patients and their treating physicians many new and effective therapeutic options. Three new medical therapies were recently approved on the basis of prolonged overall survival in castration-resistant prostate cancer patients: sipuleucel-T (Provenge), cabazitaxel (Jevtana), and abiraterone acetate (Zytiga). Additionally, there are several other promising prostate cancer agents in late-stage development, including MDV3100, PROSTVAC-VF (Prostvac), orteronel (TAK-700), and radium-223 chloride (Alpharadin), each with a novel mechanism of action. Taken together, we have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents.
几种新型药物的快速获批为前列腺癌患者及其治疗医生提供了许多新的有效治疗选择。基于前列腺癌去势抵抗患者的总生存时间延长，三种新的医学疗法最近获得批准：sipuleucel-T（Provenge）、卡巴他赛（Jevtana）和阿比特龙（Zytiga）。此外，还有其他几种处于后期开发阶段的很有前途的前列腺癌药物，包括 MDV3100、PROSTVAC-VF（Prostvac）、或特酮（TAK-700）和镭-223 氯化物（Alpharadin），每种药物都具有新的作用机制。总的来说，我们已经进入了一个药物快速开发和晚期前列腺癌治疗乐观的时期。这些患者的治疗模式正在迅速发展，需要进一步研究来确定这些新药物的最佳序贯和潜在联合应用。
